Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.

Disclosed herein are aspects of portable vaporizers to deliver aliquots of heated air to material in a furnace. The furnace is multipurposed reducing heat loss, air leakage and delays in availability of air aliquots at the proper temperature for use. By dividing the furnace with an air permeable divider and placing material in the chamber a controller selectively providing electrical power to a heating element configured to heat air furnace. Upon application of suction to the fluid passage heated air passes through a divider which shapes the head of the heated plume before the aliquot of air reaches the material. A controller in signal communications with at least one temperature sensor controls the power flow to a heater to control the temperature produced by heating element(s).

The spray application device with angled tip may comprise an applicator and an activator, where the applicator has a nozzle for delivery of a sprayable material. The spray application device may store a medication and may dispense the medication as an aerosol mist. The medication applicator may be adapted to dispense the medication through a nostril of a user directed at the posterior nasal cavity. The spray application device may be operable to release the medication in multiple doses of predetermined volume. The spray application device may be adapted for the user to self-administer the medication while positioned in any preferred physical position. A nozzle with a compliant nozzle shroud, an angled tip, and anatomically optimized nozzle geometry may direct the medication to a precise location within the posterior nasal cavity of a user.

The spray application device with angled tip may comprise an applicator and an activator, where the applicator has a nozzle for delivery of a sprayable material. The spray application device may store a medication and may dispense the medication as an aerosol mist. The medication applicator may be adapted to dispense the medication through a nostril of a user directed at the posterior nasal cavity. The spray application device may be operable to release the medication in multiple doses of predetermined volume. The spray application device may be adapted for the user to self-administer the medication while positioned in any preferred physical position. A nozzle with a compliant nozzle shroud, an angled tip, and anatomically optimized nozzle geometry may direct the medication to a precise location within the posterior nasal cavity of a user.

An adjustable bed includes a frame structure; an upper support bracket and a lower support bracket pivotally connected to the frame structure; a plurality of platforms disposed on the frame structure and supported by the upper support bracket and the lower support bracket without using hinging means; and an adjustable assembly coupled with the frame structure and the upper support bracket and the lower support bracket for operably adjusting one or more of the plurality of platforms in desired positions.

An ultrasonic electronic rhinitis therapeutic apparatus with far-infrared atomized coconut essential oil is disclosed. The apparatus includes a nasal plug part and a nasal alar part. The nasal plug part includes an insertion column disposed in a nostril. The insertion column is internally provided with a coconut powder, and a far-infrared generating tube is arranged in the coconut powder. An ultrasonic generator is arranged in the nasal alar part, and the nasal alar part is fitted on the lateral side of the nasal alar. In the disclosure, the oil and acid substance in the coconut powder are atomized by far-infrared light and are atomized under the aid of pulse ultrasonic wave in the nasal cavity to be inhaled into the internal tissues of the nasal cavity, sinus and the like.

An ultrasonic electronic rhinitis therapeutic apparatus with far-infrared atomized coconut essential oil is disclosed. The apparatus includes a nasal plug part and a nasal alar part. The nasal plug part includes an insertion column disposed in a nostril. The insertion column is internally provided with a coconut powder, and a far-infrared generating tube is arranged in the coconut powder. An ultrasonic generator is arranged in the nasal alar part, and the nasal alar part is fitted on the lateral side of the nasal alar. In the disclosure, the oil and acid substance in the coconut powder are atomized by far-infrared light and are atomized under the aid of pulse ultrasonic wave in the nasal cavity to be inhaled into the internal tissues of the nasal cavity, sinus and the like.

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

A breathing treatment delivery device is disclosed for providing atomized medicine or oxygen to a patient. The breathing treatment delivery device can include a supply device configured to dispense atomized medicine or oxygen through a dispensing end of the supply device. A cap can have a device side and a delivery side, the device side including an opening receiving and in fluid communication with the dispensing end of the supply device. A treat holder can be positioned on the delivery side of the cap. At least one aperture can be defined in the delivery side of the cap adjacent the treat holder, a pneumatic passage formed through the cap between the opening in the device side of the cap and the aperture. A patient can enjoy a piece of candy or other treat retained by the treat holder during treatment while breathing in the desired medicine or oxygen.